26-Mar-2020 | Facts and Factors
the global Insulin Glargine market in 2019 is approximately USD 5,782.92 Million. The market is anticipated to grow at a CAGR of 4.02% and is projected to reach around USD 7,609.2 Million by 2026.
Insulin Glargine is parental preparation used for the treatment of diabetes or hyperglycemic patients across the world. It is a long-acting form of drug used to treat both Type 1 and Type 2 Diabetes. Insulin Glargine shows the same effect as human insulin but differs in chemical behavior. Insulin is a kind of peptide hormone which are produced by the beta cell of the pancreas of the body system and support the metabolism process. Insulin glargine is created by the technology of recombinant DNA using a non-pathogenic laboratory-based strain of Escherichia coli (K12) as the production organism.
Browse the full “IInsulin Glargine Market By Product (Single Doase and Prefilled Syringes), By Application (Type 1 and Type 2) By Distribution Channel (Hospitals, Pharmacy, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2026" https://www.fnfresearch.com/insulin-glargine-market-by-product-single-doase-and-941
According to the diabetes statistics reports published by the Centre for the Control and Prevention of Disease (CDC) in 2017, more than 30.33 Million populations in the U.S. are suffering from Diabetes. A torpid lifestyle and a Rise in fatness, especially across the visceral organs are considered of the major factors for developing diabetes. In addition, increasing the consumption of unhealthy diets may likely boost the diabetic condition in healthy individuals. The high cost of therapy may like to curb the market. Research and development might bring huge opportunities within the forecast periods.
In product type, the market is classified into two types’ single dose and Prefilled syringes. Single dose acquires the largest market share in the year 2019. This growth is attributed due to the low cost of single doses. Pre-filled syringes are proven to be more costly than single-dose products.
Based on Application, the market is fragmented into two types: Type 1 and Type 2. Type 2 diabetes holds the largest market share in the year 2019. Type 2 diabetes is mainly caused due to deposition of fat around visceral organs. Lack of exercise, excess calories, and junk food is the major factors responsible for the deposition of visceral fat across the body.
In North America, the U.S. is the major driving country for the region. This growth is mainly associated with heavy investment in research and development. Advanced healthcare infrastructures and public affordability are major factors for the growth of the market. European countries with high per capita income like Germany, Italy, France, and the UK are the major drivers. China and India's population are the major drivers for the Asia Pacific region.
Report Scope
Report Attribute |
Details |
Market Size in 2019 |
USD 5,782.92 Million |
Projected Market Size in 2026 |
USD 7,609.2 Million |
CAGR Growth Rate |
4.02% CAGR |
Base Year |
2020 |
Forecast Years |
2020-2026 |
Key Market Players |
Sanofi Aventis, Ganlee, Biocon and many others. |
Key Segment |
By Product, By Application, By End-users, By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Some of the essential players operating in the market are Sanofi Aventis, Ganlee, Biocon, and many others.
The taxonomy of the Insulin Glargine Market by its scope and segmentation is as follows:
Global Insulin Glargine Market: Product Segment Analysis
- Single Dose Vial
- Pre-filled Syringe
Global Insulin Glargine Market: Application Segment Analysis
- Type 1 Diabetes
- Type 2 Diabetes
Global Insulin Glargine Market: End-users Segment Analysis
Global Insulin Glargine Market: By Region Segment Analysis
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- The Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East & Africa
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A - 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
